tetano
Editor, Senior Moderator
Biologicals. 2012 Jan 17. [Epub ahead of print]
Safety and immunogenicity of a monovalent MF59(?)-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.
Source
University Department of Pediatrics, DPUO, Clinical Trial Center Unit, Bambino Ges? Children's Hospital, Piazza S, Onofrio 4, 00165 Rome, Italy.
Abstract
BACKGROUND:
This Phase IV study evaluated the safety and immunogenicity of a two-dose, MF59(?)-adjuvanted (Novartis Vaccines, Marburg, Germany), monovalent, A/H1N1 pandemic influenza vaccination schedule in Human Immunodeficiency Virus (HIV) positive children and young adults.
METHODS:
A total of 83 children infected with HIV-1, and 37 non-immunocompromised, age-matched controls were enrolled. All participants received two vaccine doses administered three weeks apart. Antibody responses were assessed by haemagglutination assay at baseline, three weeks after each vaccine dose, and six months after immunization. Vaccines were evaluated according to European influenza vaccine licensure criteria.
RESULTS:
The investigational vaccine was well tolerated. After the first vaccine dose, seroconversion rates were significantly lower in HIV-positive patients (60%) than controls (82%), with GMTs of 419 and 600, respectively. No significant differences in seroconversion rates were observed between the two study groups in response to the second vaccine dose. Persisting antibody titers were similar for both HIV-positive and non-infected controls, six months after immunization.
CONCLUSION:
One dose of MF59-adjuvanted vaccine was sufficient to provide adequate levels of seroprotection against A/H1N1 influenza disease in HIV-positive children. However, a two-dose vaccination schedule may be optimal for this population.
Copyright ? 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.
PMID:
22261282
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22261282
Safety and immunogenicity of a monovalent MF59(?)-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.
Source
University Department of Pediatrics, DPUO, Clinical Trial Center Unit, Bambino Ges? Children's Hospital, Piazza S, Onofrio 4, 00165 Rome, Italy.
Abstract
BACKGROUND:
This Phase IV study evaluated the safety and immunogenicity of a two-dose, MF59(?)-adjuvanted (Novartis Vaccines, Marburg, Germany), monovalent, A/H1N1 pandemic influenza vaccination schedule in Human Immunodeficiency Virus (HIV) positive children and young adults.
METHODS:
A total of 83 children infected with HIV-1, and 37 non-immunocompromised, age-matched controls were enrolled. All participants received two vaccine doses administered three weeks apart. Antibody responses were assessed by haemagglutination assay at baseline, three weeks after each vaccine dose, and six months after immunization. Vaccines were evaluated according to European influenza vaccine licensure criteria.
RESULTS:
The investigational vaccine was well tolerated. After the first vaccine dose, seroconversion rates were significantly lower in HIV-positive patients (60%) than controls (82%), with GMTs of 419 and 600, respectively. No significant differences in seroconversion rates were observed between the two study groups in response to the second vaccine dose. Persisting antibody titers were similar for both HIV-positive and non-infected controls, six months after immunization.
CONCLUSION:
One dose of MF59-adjuvanted vaccine was sufficient to provide adequate levels of seroprotection against A/H1N1 influenza disease in HIV-positive children. However, a two-dose vaccination schedule may be optimal for this population.
Copyright ? 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.
PMID:
22261282
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22261282